Emerging drugs for the treatment of progressive familial intrahepatic cholestasis: a focus on phase II and III trials

REFERENCES

• Kamath BM, Stein P, Houwen RHJ, et al. Potential of ileal bile acid transporter inhibition as a therapeutic target in alagille syndrome and progressive familial intrahepatic cholestasis. Liver Int. 2020;40(8):1812–1822. doi: 10.1111/liv.14553
   PubMed Web of Science ®Google Scholar
• Li T, Udayan A. Bile acid metabolism and signaling in cholestasis, inflammation and cancer. Adv Pharmacol. 2015;74(1):263–302.
   PubMedGoogle Scholar
• Davit-Spraul A, Gonzales E, Baussan C, et al. Progressive familial intrahepatic cholestasis. Orphanet J Rare Dis. 2009;4(1):1–12. doi: 10.1186/1750-1172-4-1
   PubMedGoogle Scholar
• Ruth ND, Gray Z, McKay K, et al. P1248 identifying incidence of inherited metabolic disorders in patients with infantile liver disease. J Hepatol. 2014;60(1):S505. doi: 10.1016/S0168-8278(14)61408-2
   Web of Science ®Google Scholar
• Hofmann AF. The continuing importance of bile acids in liver and intestinal disease. Arch Intern Med. 1999;159(22):2647–2658. doi: 10.1001/archinte.159.22.2647
   PubMed Web of Science ®Google Scholar
• Stellaard F, Lütjohann D. Dynamics of the enterohepatic circulation of bile acids in healthy humans. Am J Physiol Gastrointest Liver Physiol. 2021;321(1):G55–66. doi: 10.1152/ajpgi.00476.2020
   PubMed Web of Science ®Google Scholar
• Keitel V, Dröge C, Häussinger D. Targeting FXR in Cholestasis. In: Handbook of Experimental Pharmacology. Springer Nature Switzerland; 2019. p. 299–324.
   Google Scholar
• Cariello M, Piccinin E, Garcia-Irigoyen O, et al. Nuclear receptor FXR, bile acids and liver damage: introducing the progressive familial intrahepatic cholestasis with FXR mutations. Biochim Biophys Acta - Mol Basis Dis. 2018;1864(4):1308–1318. doi: 10.1016/j.bbadis.2017.09.019
   PubMed Web of Science ®Google Scholar
• Kurosu H, Ogawa Y, Miyoshi M, et al. Regulation of fibroblast growth factor-23 signaling by Klotho. J Biol Chem. 2006;281(10):6120–6123. doi: 10.1074/jbc.C500457200
   PubMed Web of Science ®Google Scholar
• Jacquemin E. Progressive familial intrahepatic cholestasis. Clin Res Hepatol Gastroenterol. 2012;36(SUPPL.1):S26–35. doi: 10.1016/S2210-7401(12)70018-9
   PubMedGoogle Scholar
• Van Mil SWC, Houwen RHJ, Klomp LWJ. Genetics of familial intrahepatic cholestasis syndromes. J Med Genet. 2005;42(6):449–63.
   PubMed Web of Science ®Google Scholar
• Davit-Spraul A, Fabre M, Branchereau S, et al. ATP8B1 and ABCB11 Analysis in 62 children with normal gamma-glutamyl transferase progressive familial intrahepatic cholestasis (PFIC): phenotypic differences between PFIC1 and PFIC2 and natural history. Hepatology. 2010;51(5):1645–1655. doi: 10.1002/hep.23539
   PubMed Web of Science ®Google Scholar
• Groen A, Romero MR, Kunne C, et al. Complementary functions of the flippase ATP8B1 and the floppase ABCB4 in maintaining canalicular membrane integrity. Gastroenterology. 2011;141(5):1927–1937.e4.
   PubMed Web of Science ®Google Scholar
• Srivastava A. Progressive familial Intrahepatic Cholestasis. J Clin Exp Hepatol. 2014;4(1):25–36. doi: 10.1016/j.jceh.2013.10.005
   PubMedGoogle Scholar
• Vitale G, Gitto S, Vukotic R, et al. Familial intrahepatic cholestasis: new and wide perspectives. Dig Liver Dis. 2019;51(7):922–933. doi: 10.1016/j.dld.2019.04.013
   PubMedGoogle Scholar
• Paulusma CC, de Waart DR, Kunne C, et al. Activity of the bile salt export pump (ABCB11) is critically dependent on canalicular membrane cholesterol content. J Biol Chem. 2009;284(15):9947–9954. doi: 10.1074/jbc.M808667200
   PubMed Web of Science ®Google Scholar
• Lemoine C, Superina R. Surgical diversion of enterohepatic circulation in pediatric cholestasis. Semin Pediatr Surg. 2020;29(4):150946. doi: 10.1016/j.sempedsurg.2020.150946
   PubMed Web of Science ®Google Scholar
• Jansen PLM, Strautnieks SS, Jacquemin E, et al.. Hepatocanalicular bile salt export pump deficiency in patients with progressive familial intrahepatic cholestasis. Gastroenterology. 1999;117(6):1370–1379. doi: 10.1016/S0016-5085(99)70287-8
   PubMed Web of Science ®Google Scholar
• Strautnieks SS, Byrne JA, Pawlikowska L, et al. Severe Bile Salt Export Pump Deficiency: 82 Different ABCB11 Mutations in 109 Families. Gastroenterology. 2008;134(4):1203–14.
   PubMed Web of Science ®Google Scholar
• Evason K, Bove KE, Finegold MJ, et al. Morphologic findings in progressive familial intrahepatic cholestasis 2 (PFIC2): correlation with genetic and immunohistochemical studies. Am J Surg Pathol. 2011;35(5):687–696. doi: 10.1097/PAS.0b013e318212ec87
   PubMed Web of Science ®Google Scholar
• van Wessel DBE, Thompson RJ, Gonzales E, et al. Genotype correlates with the natural history of severe bile salt export pump deficiency. J Hepatol. 2020;73(1):84–93.
   PubMed Web of Science ®Google Scholar
• Crawford AR, Smith AJ, Hatch VC, et al. Hepatic secretion of phospholipid vesicles in the mouse critically depends on mdr2 or MDR3 P-glycoprotein expression: Visualization by electron microscopy. J Clin Invest. 1997;100(10):2562–7.
   PubMed Web of Science ®Google Scholar
• Alissa FT, Jaffe R, Shneider BL. Update on progressive familial intrahepatic cholestasis. J Pediatr Gastroenterol Nutr. 2008;46(3):241–252. doi: 10.1097/MPG.0b013e3181596060
   PubMed Web of Science ®Google Scholar
• Bosma PJ, Wits M, Oude-Elferink RPJ. Gene therapy for progressive familial intrahepatic cholestasis: Current progress and future prospects. Int J Mol Sci. 2021;22(1):1–13.
   Web of Science ®Google Scholar
• Bull LN, Thompson RJ. Progressive familial Intrahepatic Cholestasis. Clin Liver Dis. 2018;22(4):657–669. doi: 10.1016/j.cld.2018.06.003
   PubMed Web of Science ®Google Scholar
• Sambrotta M, Strautnieks S, Papouli E, et al. Mutations in TJP2 cause progressive cholestatic liver disease. Nat Genet. 2014;46(4):326–328. doi: 10.1038/ng.2918
   PubMed Web of Science ®Google Scholar
• Xu J, Kausalya PJ, Van Hul N, et al.. Protective Functions of ZO-2/Tjp2 Expressed in Hepatocytes and Cholangiocytes Against Liver Injury and Cholestasis. Gastroenterology. 2021;160(6):2103–2118. doi: 10.1053/j.gastro.2021.01.027
   PubMed Web of Science ®Google Scholar
• Martínez-García J, Molina A, González-Aseguinolaza G, et al.. Gene Therapy for Acquired and Genetic Cholestasis. Biomedicines. 2022;10(6):1–20. doi: 10.3390/biomedicines10061238
   Web of Science ®Google Scholar
• Gomez-Ospina N, Potter CJ, Xiao R, et al. Mutations in the nuclear bile acid receptor FXR cause progressive familial intrahepatic cholestasis. Nat Commun. 2016;7(1):1–8. doi: 10.1038/ncomms10713
   Google Scholar
• Qiu YL, Gong JY, Feng JY, et al. Defects in myosin VB are associated with a spectrum of previously undiagnosed low γ-glutamyltransferase cholestasis. Hepatology. 2017;65(5):1655–1669. doi: 10.1002/hep.29020
   PubMed Web of Science ®Google Scholar
• Aldrian D, Vogel GF, Frey TK, et al. Congenital diarrhea and cholestatic liver disease: phenotypic spectrum associated with myo5b mutations. J Clin Med. 2021;10(3):1–15. doi: 10.3390/jcm10030481
   Web of Science ®Google Scholar
• Girard M, Lacaille F, Verkarre V, et al. MYO5B and bile salt export pump contribute to cholestatic liver disorder in microvillous inclusion disease. Hepatology. 2014;60(1):301–310. doi: 10.1002/hep.26974
   PubMed Web of Science ®Google Scholar
• Uyar Aksu N, Görükmez O, Görükmez Ö, et al. A Novel Homozygous Mutation in the MYO5B Gene Associated With Normal-Gamma-Glutamyl Transferase Progressive Familial Intrahepatic Cholestasis. Cureus. 2021;13(11):1–5.
   Web of Science ®Google Scholar
• Kamath BM, Chen Z, Romero R, et al. Quality of life and its determinants in a Multicenter Cohort of Children with alagille syndrome. J Pediatr. 2015;167(2):390–396.e3. doi: 10.1016/j.jpeds.2015.04.077
   PubMed Web of Science ®Google Scholar
• Lee WS, Chai PF, Looi LM. Progressive familial intrahepatic cholestasis in Malaysian patients - A report of five cases. Med J Malaysia. 2009;64(3):216–9.
   PubMedGoogle Scholar
• Schukfeh N, Metzelder ML, Petersen C, et al. Normalization of serum bile acids after partial external biliary diversion indicates an excellent long-term outcome in children with progressive familial intrahepatic cholestasis. J Pediatr Surg. 2012;47(3):501–505. doi: 10.1016/j.jpedsurg.2011.08.010
   PubMed Web of Science ®Google Scholar
• Yang H, Porte RJ, Verkade HJ, et al. Partial external biliary diversion in children with progressive familial intrahepatic cholestasis and alagille disease. J Pediatr Gastroenterol Nutr. 2009;49(2):216–221. doi: 10.1097/MPG.0b013e31819a4e3d
   PubMed Web of Science ®Google Scholar
• Jones-Hughes T, Campbell J, Crathorne L. Epidemiology and burden of progressive familial intrahepatic cholestasis: a systematic review. Orphanet J Rare Dis. 2021;16(1):1–14. doi: 10.1186/s13023-021-01884-4
   PubMed Web of Science ®Google Scholar
• Mehl A, Bohorquez H, Serrano MS, et al. Liver transplantation and the management of progressive familial intrahepatic cholestasis in children. World J Transplant. 2016;6(2):278.
   PubMedGoogle Scholar
• Englert C, Grabhorn E, Richter A, et al. Liver transplantation in children with progressive familial intrahepatic cholestasis. Transplantation. 2007;84(10):1361–1363. doi: 10.1097/01.tp.0000282869.94152.4f
   PubMed Web of Science ®Google Scholar
• Baker A, Kerkar N, Todorova L, et al. Systematic review of progressive familial intrahepatic cholestasis. Clin Res Hepatol Gastroenterol. 2019;43(1):20–36. doi: 10.1016/j.clinre.2018.07.010
   PubMed Web of Science ®Google Scholar
• Kubitz R, Dröge C, Kluge S, et al. Autoimmune BSEP disease: disease recurrence after liver transplantation for progressive familial intrahepatic cholestasis. Clin Rev Allergy Immunol. 2015;48(2–3):273–284. doi: 10.1007/s12016-014-8457-4
   PubMed Web of Science ®Google Scholar
• Deeks ED. Odevixibat: First Approval. Drugs. 2021;81(15):1781–6.
   PubMed Web of Science ®Google Scholar
• Jacquemin E. Role of multidrug resistance 3 deficiency in pediatric and adult liver disease: one gene for three diseases. Semin Liver Dis. 2001;21(4):551–562. doi: 10.1055/s-2001-19033
   PubMed Web of Science ®Google Scholar
• Gordo-Gilart R, Andueza S, Hierro L, et al.. Functional analysis of ABCB4 mutations relates clinical outcomes of progressive familial intrahepatic cholestasis type 3 to the degree of MDR3 floppase activity. Gut. 2015;64(1):147–155. doi: 10.1136/gutjnl-2014-306896
   PubMed Web of Science ®Google Scholar
• European Association for the Study of the Liver. EASL Clinical Practice Guidelines: Management of cholestatic liver diseases. J Hepatol [Internet]. 2009;51(2):237–267. Available from: http://dx.doi.org/10.1016/j.jhep.2009.04.009
   PubMed Web of Science ®Google Scholar
• Stapelbroek JM, van Erpecum KJ, Klomp LWJ, et al. Liver disease associated with canalicular transport defects: Current and future therapies. J Hepatol. 2010;52(2):258–271. doi: 10.1016/j.jhep.2009.11.012
   PubMed Web of Science ®Google Scholar
• Fickert P, Wagner M, Marschall HU, et al.. 24-norUrsodeoxycholic acid is superior to ursodeoxycholic acid in the treatment of sclerosing cholangitis in Mdr2 (Abcb4) knockout mice. Gastroenterology. 2006;130(2):465–481. doi: 10.1053/j.gastro.2005.10.018
   PubMed Web of Science ®Google Scholar
• Fickert P, Hirschfield GM, Denk G, et al. norUrsodeoxycholic acid improves cholestasis in primary sclerosing cholangitis. J Hepatol. 2017;67(3):549–558. doi: 10.1016/j.jhep.2017.05.009
   PubMed Web of Science ®Google Scholar
• Whitington PF, Freese DK, Alonso EM, et al. Clinical and biochemical findings in progressive familial intrahepatic cholestasis. J Pediatr Gastroenterol Nutr. 1994;18(2):134–141. doi: 10.1002/j.1536-4801.1994.tb11143.x
   PubMed Web of Science ®Google Scholar
• Bhalerao A, Mannu GS. Management of Pruritus in chronic liver disease. Dermatol Res Pract. 2015; 2015.
   PubMedGoogle Scholar
• Hegade VS, Kendrick SFW, Jones DEJ. Drug treatment of pruritus in liver diseases. Clin Med J R Coll Physicians London. 2015;15(4):351–357. doi: 10.7861/clinmedicine.15-4-351
   Google Scholar
• Scaldaferri F, Pizzoferrato M, Ponziani FR, et al. Use and indications of cholestyramine and bile acid sequestrants. Intern Emerg Med. 2013;8(3):205–210. doi: 10.1007/s11739-011-0653-0
   PubMed Web of Science ®Google Scholar
• Li T, Chiang JYL. Mechanism of rifampicin and pregnane X receptor inhibition of human cholesterol 7α-hydroxylase gene transcription. Am J Physiol Gastrointest Liver Physiol. 2005;288(1 51–1):74–84.
   Web of Science ®Google Scholar
• Beuers U, Wolters F, Oude Elferink RPJ. Mechanisms of pruritus in cholestasis: understanding and treating the itch. Nat Rev Gastroenterol Hepatol. 2023;20(1):26–36. doi: 10.1038/s41575-022-00687-7
   PubMed Web of Science ®Google Scholar
• Wietholtz H, Marschall HU, Jan S, et al. Stimulation of bile acid 6α-hydroxylation by rifampin. J Hepatol. 1996;24(6):713–718. doi: 10.1016/S0168-8278(96)80268-6
   PubMed Web of Science ®Google Scholar
• Marschall H, Wagner M, Zollner G, et al.. Complementary Stimulation of Hepatobiliary Transport and Detoxification Systems by Rifampicin and Ursodeoxycholic Acid in Humans. Gastroenterology. 2005;129(2):476–485. doi: 10.1016/j.gastro.2005.05.009
   PubMed Web of Science ®Google Scholar
• Murray-Brown FL. Naltrexone for cholestatic itch: A systematic review. BMJ Support Palliat Care. 2021;11(2):217–225. doi: 10.1136/bmjspcare-2020-002801
   PubMed Web of Science ®Google Scholar
• Yang CH, Perumpail BJ, Yoo ER, et al. Nutritional needs and support for children with chronic liver disease. Nutrients. 2017;9(10):1–16. doi: 10.3390/nu9101127
   Web of Science ®Google Scholar
• Agarwal S, Lal BB, Rawat D, et al. Progressive familial Intrahepatic Cholestasis (PFIC) in Indian children: clinical spectrum and outcome. J Clin Exp Hepatol. 2016;6(3):203–208. doi: 10.1016/j.jceh.2016.05.003
   PubMedGoogle Scholar
• Whitington PF, Whitington GL. Partial external diversion of bile for the treatment of intractable pruritus associated with intrahepatic cholestasis. Gastroenterology. 1988;95(1):130–136. doi: 10.1016/0016-5085(88)90301-0
   PubMed Web of Science ®Google Scholar
• Gunaydin M, Tander B, Demirel D, et al. Different techniques for biliary diversion in progressive familial intrahepatic cholestasis. J Pediatr Surg. 2016;51(3):386–389. doi: 10.1016/j.jpedsurg.2015.08.011
   PubMed Web of Science ®Google Scholar
• Van Vaisberg V, Tannuri ACA, Lima FR, et al. Ileal exclusion for pruritus treatment in children with progressive familial intrahepatic cholestasis and other cholestatic diseases. J Pediatr Surg. 2020;55(7):1385–1391. doi: 10.1016/j.jpedsurg.2019.09.018
   PubMed Web of Science ®Google Scholar
• Usui M, Isaji S, Das BC, et al. Liver retransplantation with external biliary diversion for progressive familial intrahepatic cholestasis type 1: a case report. Pediatr Transplant. 2009;13(5):611–614. doi: 10.1111/j.1399-3046.2008.00878.x
   PubMed Web of Science ®Google Scholar
• Wang KS, Tiao G, Bass LM, et al. Analysis of surgical interruption of the enterohepatic circulation as a treatment for pediatric cholestasis. Hepatology. 2017;65(5):1645–1654. doi: 10.1002/hep.29019
   PubMed Web of Science ®Google Scholar
• Hüpper MN, Pichler J, Huber WD, et al.. Surgical versus Medical Management of Progressive Familial Intrahepatic Cholestasis—Case Compilation and Review of the Literature. Children. 2023;10(6):949. doi: 10.3390/children10060949
   PubMedGoogle Scholar
• Van Der Woerd WL, Houwen RHJ, Van De Graaf SFJ. Current and future therapies for inherited cholestatic liver diseases. World J Gastroenterol. 2017;23(5):763–75.
   PubMed Web of Science ®Google Scholar
• Pfister ED, Jaeger VK, Karch A, et al. Native liver survival in bile salt export pump deficiency: results of a retrospective cohort study. Hepatol Commun. 2023;7(4). 10.1097/HC9.0000000000000092
   PubMed Web of Science ®Google Scholar
• Bull LN, Pawlikowska L, Strautnieks S, et al. Outcomes of surgical management of familial intrahepatic cholestasis 1 and bile salt export protein deficiencies. Hepatol Commun. 2018;2(5):515–528. doi: 10.1002/hep4.1168
   PubMed Web of Science ®Google Scholar
• Kaliciński PJ, Ismail H, Jankowska I, et al. Surgical Treatment of Progressive Familial Intrahepatic Cholestasis: Comparison of Partial External Biliary Diversion and Ileal Bypass. Eur J Pediatr Surg. 2003;13(5):307–11.
   PubMed Web of Science ®Google Scholar
• Bjornland K, Hukkinen M, Gatzinsky V, et al. Partial biliary diversion may promote long-term relief of pruritus and native liver survival in children with cholestatic liver diseases. Eur J Pediatr Surg. 2021;31(4):341–346. doi: 10.1055/s-0040-1714657
   PubMed Web of Science ®Google Scholar
• Miyagawa-Hayashino A, Egawa H, Yorifuji T, et al. Allograft Steatohepatitis in Progressive Familial Intrahepatic Cholestasis Type 1 After Living Donor Liver Transplantation. Liver Transplant. 2007;13(5):767–8.
   PubMedGoogle Scholar
• Aydogdu S, Cakir M, Arikan C, et al. Liver transplantation for progressive familial intrahepatic cholestasis: clinical and histopathological findings, outcome and impact on growth. Pediatr Transplant. 2007;11(6):634–640. doi: 10.1111/j.1399-3046.2007.00722.x
   PubMed Web of Science ®Google Scholar
• Nicastro E, Stephenne X, Smets F, et al. Recovery of graft steatosis and protein-losing enteropathy after biliary diversion in a PFIC 1 liver transplanted child. Pediatr Transplant. 2012;16(5):177–182. doi: 10.1111/j.1399-3046.2011.01514.x
   Web of Science ®Google Scholar
• Mali VP, Fukuda A, Shigeta T, et al. Total internal biliary diversion during liver transplantation for type 1 progressive familial intrahepatic cholestasis: a novel approach. Pediatr Transplant. 2016;20(7):981–986. doi: 10.1111/petr.12782
   PubMed Web of Science ®Google Scholar
• Knisely AS, Strautnieks SS, Meier Y, et al. Hepatocellular carcinoma in ten children under five years of age with bile salt export pump deficiency. Hepatology. 2006;44(2):478–486. doi: 10.1002/hep.21287
   PubMed Web of Science ®Google Scholar
• Dröge C, Bonus M, Baumann U, et al. Sequencing of FIC1, BSEP and MDR3 in a large cohort of patients with cholestasis revealed a high number of different genetic variants. J Hepatol. 2017;67(6):1253–1264. doi: 10.1016/j.jhep.2017.07.004
   PubMed Web of Science ®Google Scholar
• Jara P, Hierro L, Martínez-Fernández P, et al. Recurrence of bile salt export pump deficiency after liver transplantation. N Engl J Med. 2009;361(14):1359–1367. doi: 10.1056/NEJMoa0901075
   PubMed Web of Science ®Google Scholar
• Keitel V, Burdelski M, Vojnisek Z, et al. De Novo bile salt transporter antibodies as a possible cause of recurrent graft failure after liver transplantation: a novel mechanism of cholestasis. Hepatology. 2009;50(2):510–517. doi: 10.1002/hep.23083
   PubMed Web of Science ®Google Scholar
• Stindt J, Kluge S, Dröge C, et al. Bile salt export pump-reactive antibodies form a polyclonal, multi-inhibitory response in antibody-induced bile salt export pump deficiency. Hepatology. 2016;63(2):524–537. doi: 10.1002/hep.28311
   PubMed Web of Science ®Google Scholar
• Siebold L, Dick AAS, Thompson R, et al. Recurrent low gamma-glutamyl transpeptidase cholestasis following liver transplantation for bile salt export pump (BSEP) disease (Posttransplant recurrent BSEP disease). Liver Transplant. 2010;16(7):856–863. doi: 10.1002/lt.22074
   PubMed Web of Science ®Google Scholar
• Grammatikopoulos T, Knisely AS, Dhawan A, et al. Anti-CD20 monoclonal antibody therapy in functional bile salt export pump deficiency after liver transplantation. J Pediatr Gastroenterol Nutr. 2015;60(6):e50–3. doi: 10.1097/MPG.0000000000000238
   PubMedGoogle Scholar
• Jadlowiec CC, Taner T. Liver transplantation: Current status and challenges. World J Gastroenterol. 2016;22(18):4438–45.
   PubMed Web of Science ®Google Scholar
• Graffner H, Gillberg PG, Rikner L, et al. The ileal bile acid transporter inhibitor A4250 decreases serum bile acids by interrupting the enterohepatic circulation. Aliment Pharmacol Ther. 2016;43(2):303–310. doi: 10.1111/apt.13457
   PubMed Web of Science ®Google Scholar
• European Medicines Agency. Bylvay (odevixibat) Medicine Overview [Internet]. 2021 [cited 2023 Oct 24]. Available from: https://www.ema.europa.eu/en/documents/overview/mylotarg-epar-summary-public_en.pdf
   Google Scholar
• Albireo Pharma. Bylvay Prescribing Information [Internet]. 2023 [cited 2023 Oct 24]. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/215498s000lbl.pdf
   Google Scholar
• European Medicines Agency. Bylvay Summary of Product Characteristics [Internet]. 2021 [cited 2023 Oct 24]. Available from: https://www.ema.europa.eu/en/documents/product-information/bylvay-epar-product-information_en.pdf
   Google Scholar
• Thompson RJ, Arnell H, Artan R, et al. Odevixibat treatment in progressive familial intrahepatic cholestasis: a randomised, placebo-controlled, phase 3 trial. Lancet Gastroenterol Hepatol. 2022;7(9):830–842. doi: 10.1016/S2468-1253(22)00093-0.
   PubMed Web of Science ®Google Scholar
• Ellinger P, Stindt J, Dröge C, et al. Partial external biliary diversion in bile salt export pump deficiency: association between outcome and mutation. World J Gastroenterol. 2017;23(29):5295–5303. doi: 10.3748/wjg.v23.i29.5295
   PubMed Web of Science ®Google Scholar
• Thompson RJ, Artan R, Baumann U, et al. Interim results from an ongoing, open-label, single-arm trial of odevixibat in progressive familial intrahepatic cholestasis. JHEP Rep. 2023;5(8):100782. doi: 10.1016/j.jhepr.2023.100782
   PubMedGoogle Scholar
• Gonzales E, Hardikar W, Stormon M, et al. Efficacy and safety of maralixibat treatment in patients with alagille syndrome and cholestatic pruritus (ICONIC): a randomised phase 2 study. Lancet. 2021;398(10311):1581–1592. doi: 10.1016/S0140-6736(21)01256-3
   PubMed Web of Science ®Google Scholar
• Kunst RF, de Waart DR, Wolters F, et al. Systemic ASBT inactivation protects against liver damage in obstructive cholestasis in mice. JHEP Rep. 2022;4(11):100573. doi: 10.1016/j.jhepr.2022.100573.
   PubMedGoogle Scholar
• Food & Drug Administration. Orphan Drug Designations and Approvals [Internet]. 2021. Available from: https://www.accessdata.fda.gov/scripts/opdlisting/oopd/detailedIndex.cfm?cfgridkey=370912
   Google Scholar
• European Medicines Agency. Orphan Maintenance Assessment report Bylvay (Odevixibat) [Internet]. 2021. Available from: https://www.ema.europa.eu/en/medicines/human/EPAR/evrysdi
   Google Scholar
• Ipsen. The acquisition of Albireo [Internet]. 2023. Available from: https://www.ipsen.com/websites/ipsen_com_v2/wp-content/uploads/2023/01/23204433/The-acquistion-of-Albireo.pdf
   Google Scholar
• Committee for Medicinal Products for Human Use. Assessment report - Bylvay (Odevixibat). EMA/319560/2021. 2021.
   Google Scholar
• Albireo Pharma. Current Report exhibit 99.2 [Internet]. 2020. Available from: https://www.sec.gov/Archives/edgar/data/1322505/000110465920008111/tm205897d2_ex99-2.htm
   Google Scholar
• Felzen A, van Wessel DBE, Gonzales E, et al. Genotype-phenotype relationships of truncating mutations, p.E297G and p.D482G in bile salt export pump deficiency. JHEP Rep. 2023;5(2):100626. doi: 10.1016/j.jhepr.2022.100626
   PubMedGoogle Scholar
• Albireo Pharma. Albireo Reports Q3 2022 Financial Results and Business Update. 2022.
   Google Scholar
• Ipsen. Ipsen delivers solid sales growth in the first nine months of 2023 and confirms its full-year guidance. YTD 2023 - sales announcement. 2023.
   Google Scholar
• Ipsen. U.S. FDA approves Bylvay® for patients living with cholestatic pruritus due to Alagille syndrome. 2023.
   Google Scholar
• Tandvårds- och läkemedelsförmånsverket (TLV). TLV Decision Bylvay. 2023.
   Google Scholar
• Zorginstituut Nederland. GVS advice odevixibat (Bylvay®). 2023.
   Google Scholar
• Van de Peppel IP, Verkade HJ, Jonker JW. Metabolic consequences of ileal interruption of the enterohepatic circulation of bile acids. Am J Physiol Gastrointest Liver Physiol. 2020;319(5):G619–25.
   PubMed Web of Science ®Google Scholar
• Mareux E, Lapalus M, Ben Saad A, et al. In vitro rescue of the bile acid transport function of ABCB11 variants by CFTR potentiators. Int J Mol Sci. 2022;23(18):10758. doi: 10.3390/ijms231810758
   PubMed Web of Science ®Google Scholar
• Matsubara T, Li F, Gonzalez FJ. FXR signaling in the enterohepatic system. Mol Cell Endocrinol. 2013;368(1–2):17–29. doi: 10.1016/j.mce.2012.05.004
   PubMed Web of Science ®Google Scholar
• Floreani A, Gabbia D, De Martin S. Update on the Pharmacological Treatment of Primary Biliary Cholangitis. Biomedicines. 2022;10(8):1–17. doi: 10.3390/biomedicines10082033
   Web of Science ®Google Scholar
• Gonzales E, Jacquemin E. Mutation specific drug therapy for progressive familial or benign recurrent intrahepatic cholestasis: a new tool in a near future? J Hepatol. 2010;53(2):385–387. doi: 10.1016/j.jhep.2010.03.012
   PubMed Web of Science ®Google Scholar
• Garrison P, Bangs JD. p97 Inhibitor CB-5083 Blocks ERAD in Trypanosoma brucei. Mol Biochem Parasitol. 2020;239(Sep):111313.
   PubMedGoogle Scholar
• Hayashi H, Sugiyama Y. 4-phenylbutyrate enhances the cell surface expression and the transport capacity of wild-type and mutated bile salt export pumps. Hepatology. 2007;45(6):1506–1516. doi: 10.1002/hep.21630
   PubMed Web of Science ®Google Scholar
• Mareux E, Lapalus M, Amzal R, et al. Functional rescue of an ABCB11 mutant by ivacaftor: a new targeted pharmacotherapy approach in bile salt export pump deficiency. Liver Int. 2020;40(8):1917–1925. doi: 10.1111/liv.14518
   PubMed Web of Science ®Google Scholar
• European Medicines Agency. Livmarli Summary of Product Characteristics [Internet]. 2022 [cited 2023 Oct 26]. Available from: https://www.ema.europa.eu/en/documents/product-information/livmarli-epar-product-information_en.pdf
   Google Scholar
• Food & Drug Administration. Livmarli Prescribing Information [Internet]. 2024 [cited 2023 Oct 19]. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/214662s000lbl.pdf
   Google Scholar
• European Medicines Agency. Livmarli Medicine Overview [Internet]. 2022 [cited 2023 Oct 19]. Available from: https://www.ema.europa.eu/en/documents/overview/livmarli-epar-medicine-overview_en.pdf
   Google Scholar
• Mirum Pharma. Mirum Submits for European Approval of LIVMARLI in Progressive Familial Intrahepatic Cholestasis [Internet]. Available from: https://ir.mirumpharma.com/news-events/News/news-details/2023/Mirum-Submits-for-European-Approval-of-LIVMARLI-in-Progressive-Familial-Intrahepatic-Cholestasis/default.aspx
   Google Scholar
• Mirum Pharma. Mirum Pharmaceuticals Announces Data from EMBARK Phase 2b Study for Biliary Atresia. Available from: https://ir.mirumpharma.com/news-events/News/news-details/2023/Mirum-Pharmaceuticals-Announces-Data-from-EMBARK-Phase-2b-Study-for-Biliary-Atresia/default.aspx
   Google Scholar
• Loomes KM, Squires RH, Kelly D, et al. Maralixibat for the treatment of PFIC: long-term, IBAT inhibition in an open-label, phase 2 study. Hepatol Commun. 2022;6(9):2379–2390. doi: 10.1002/hep4.1980.
   PubMed Web of Science ®Google Scholar
• Miethke A, Moukarzel A, Porta G, et al. Efficacy and Safety of Maralixibat in Patients with Progressive Familial Intrahepatic Cholestasis (MARCH-PFIC): A Randomized Placebo-Controlled Phase 3 Study. In: Journal of pediatric gastroenterology and nutrition. 2023. p. 709‐710.
   PubMedGoogle Scholar
• A Study to Evaluate the Efficacy and Safety of Maralixibat in Subjects With Progressive Familial Intrahepatic Cholestasis (MARCH-PFIC) NCT03905330 [Internet]. 2023 [cited 2023 Dec 8]. Available from: https://clinicaltrials.gov/study/NCT03905330
   Google Scholar
• Miethke A, Moukarzel A, Porta G, et al. Analysis of safety in maralixibat-treated participants with progressive familial intrahepatic cholestasis: data from MARCH-PFIC. J Hepatol. 2023;78:S387–8. 10.1016/S0168-8278(23)01039-5
   Web of Science ®Google Scholar
• Thompson R, Mogul D, Nunes T, et al. Maralixibat leads to significant reductions in pruritus and improvements in sleep for children with progressive familial intrahepatic cholestasis: data from MARCH-PFIC. J Hepatol. 2023;78:S370. 10.1016/S0168-8278(23)01010-3
   Web of Science ®Google Scholar
• D’Antiga L, Miethke A, Mogul D, et al. Maralixibat leads to significant reductions in bilirubin for patients with progressive familial intrahepatic cholestasis: data from MARCH-PFIC. J Hepatol. 2023;78:S61. 10.1016/S0168-8278(23)00526-3
   Web of Science ®Google Scholar
• Miethke AG, Moukarzel A, Porta G, et al. Long-Term Maintenance of Response and Improved Liver Health With Maralixibat in Patients With Progressive Familial Intrahepatic Cholestasis (PFIC): 2-Year Data From the MARCH-ON Study. In: American Association for the Study of Liver Diseases (AASLD) The Liver Meeting [Internet]. 2023. p. P5048C. Available from: https://mirumpharma.com/wp-content/uploads/2023/11/Thompson-RJ-AASLD-2023-Longterm-maintenance-of-response-and-improved-liver-health-with-MRX-in-PFIC.pdf
   Google Scholar
• Nakano S, Osaka S, Sabu Y, et al. Effect of food on the pharmacokinetics and therapeutic efficacy of 4-phenylbutyrate in progressive familial intrahepatic cholestasis. Sci Rep. 2019;9(1):1–12. doi: 10.1038/s41598-019-53628-x
   PubMedGoogle Scholar
• Lam P, Pearson CL, Soroka CJ, et al. Levels of plasma membrane expression in progressive and benign mutations of the bile salt export pump (Bsep/Abcb11) correlate with severity of cholestatic diseases. Am J Physiol - Cell Physiol. 2007;293(5):1709–16.
   Web of Science ®Google Scholar
• Hayashi H, Inamura K, Aida K, et al. AP2 adaptor complex mediates bile salt export pump internalization and modulates its hepatocanalicular expression and transport function. Hepatology. 2012;55(6):1889–1900. doi: 10.1002/hep.25591
   PubMed Web of Science ®Google Scholar
• Gonzales E, Grosse B, Cassio D, et al. Successful mutation-specific chaperone therapy with 4-phenylbutyrate in a child with progressive familial intrahepatic cholestasis type 2. J Hepatol. 2012;57(3):695–698. doi: 10.1016/j.jhep.2012.04.017
   PubMed Web of Science ®Google Scholar
• Gonzales E, Grosse B, Schuller B, et al. Targeted pharmacotherapy in progressive familial intrahepatic cholestasis type 2: evidence for improvement of cholestasis with 4-phenylbutyrate. Hepatology. 2015;62(2):558–566. doi: 10.1002/hep.27767
   PubMed Web of Science ®Google Scholar
• Naoi S, Hayashi H, Inoue T, et al. Improved liver function and relieved pruritus after 4-phenylbutyrate therapy in a patient with progressive familial intrahepatic cholestasis type 2. J Pediatr. 2014;164(5):1219–1227.e3. doi: 10.1016/j.jpeds.2013.12.032
   PubMed Web of Science ®Google Scholar
• Mareux E, Lapalus M, Ben-Saad A, et al. In vitro functional rescue by ivacaftor of an ABCB11 variant involved in PFIC2 and intrahepatic cholestasis of pregnancy. Orphanet J Rare Dis. 2021;16(1):1–4. doi: 10.1186/s13023-021-02125-4
   PubMed Web of Science ®Google Scholar
• Caballero-Camino FJ, Rodrigues PM, Wångsell F, et al. A3907, a systemic ASBT inhibitor, improves cholestasis in mice by multiorgan activity and shows translational relevance to humans. Hepatology. 2023;78(3):709–726. doi: 10.1097/HEP.0000000000000376.
   PubMed Web of Science ®Google Scholar
• Trauner M, Gulamhusein A, Hameed B, et al. The nonsteroidal farnesoid X receptor agonist cilofexor (GS-9674) improves markers of Cholestasis and liver injury in patients with primary sclerosing cholangitis. Hepatology. 2019;70(3):788–801. doi: 10.1002/hep.30509
   PubMed Web of Science ®Google Scholar
• Kowdley K V., Vuppalanchi R, Levy C, et al. A randomized, placebo-controlled, phase II study of obeticholic acid for primary sclerosing cholangitis. J Hepatol. 2020;73(1):94–101.
   PubMed Web of Science ®Google Scholar
• Mayo MJ, Wigg AJ, Leggett BA, et al. NGM282 for treatment of patients with primary biliary cholangitis: a multicenter, randomized, double-blind, placebo-controlled trial. Hepatol Commun. 2018;2(9):1037–1050. doi: 10.1002/hep4.1209
   PubMed Web of Science ®Google Scholar
• Food & Drug Administration. OCALIVA® (obeticholic acid) Prescribing Information [Internet]. 2016. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/207999s008lbl.pdf
   Google Scholar
• European Medicines Agency. Ocaliva Summary of Product Characteristics [Internet]. 2022. Available from: https://www.ema.europa.eu/en/documents/product-information/ocaliva-epar-product-information_en.pdf
   Google Scholar
• Pellicciari R, Fiorucci S, Camaioni E, et al. 6r-Ethyl-Chenodeoxycholic Acid (6-ECDCA), a Potent and Selective FXR Agonist Endowed with Anticholestatic Activity. Society. 2002;45(17):15–8.
   Google Scholar
• Nevens F, Andreone P, Mazzella G, et al. A placebo-controlled trial of obeticholic acid in primary biliary cholangitis. N Engl J Med. 2016;375(7):631–643. doi: 10.1056/NEJMoa1509840
   PubMed Web of Science ®Google Scholar
• Neuschwander-Tetri BA, Loomba R, Sanyal AJ, et al. Farnesoid X nuclear receptor ligand obeticholic acid for non-cirrhotic, non-alcoholic steatohepatitis (FLINT): a multicentre, randomised, placebo-controlled trial. Lancet. 2015;385(9972):956–965. doi: 10.1016/S0140-6736(14)61933-4
   PubMed Web of Science ®Google Scholar
• Kunst RF, Bolt I, van Dasselaar RDJ, et al. Combined inhibition of bile salt synthesis and intestinal uptake reduces cholestatic liver damage and colonic bile salts in mice. JHEP rep. 2023;6(1):100917.
   PubMedGoogle Scholar
• Soroka CJ, Boyer JL Biosynthesis and trafficking of the bile salt export pump, BSEP: Therapeutic implications of BSEP mutations. Mol Aspects Med. 2014;37:3–14. 10.1016/j.mam.2013.05.001
   PubMed Web of Science ®Google Scholar
• Jacquemin E, Hermans D, Myara A, et al. Ursodeoxycholic acid therapy in pediatric patients with progressive familial intrahepatic cholestasis. Hepatology. 1997;25(3):519–523. doi: 10.1002/hep.510250303
   PubMed Web of Science ®Google Scholar
• Pepe A, Colucci A, Carucci M, et al. Case report: add-on treatment with odevixibat in a new subtype of progressive familial intrahepatic cholestasis broadens the therapeutic horizon of genetic cholestasis. Front Pediatr. 2023;11(February):1–5. doi: 10.3389/fped.2023.1061535
   Google Scholar
• Di Giorgio A, Sciveres M, Fuoti M, et al. Treatment with an ileal bile acid transporter inhibitor in patients with TJP2 deficiency. Clin Res Hepatol Gastroenterol. 2023;47(8):102185. doi: 10.1016/j.clinre.2023.102185
   PubMed Web of Science ®Google Scholar
• Misawa T, Hayashi H, Sugiyama Y, et al. Discovery and structural development of small molecules that enhance transport activity of bile salt export pump mutant associated with progressive familial intrahepatic cholestasis type 2. Bioorganic Med Chem. 2012;20(9):2940–2949. doi: 10.1016/j.bmc.2012.03.016
   PubMed Web of Science ®Google Scholar
• Luo J, Ko B, Elliott M, et al. Liver disease: a nontumorigenic variant of FGF19 treats cholestatic liver diseases. Sci Transl Med. 2014;6(247):1–12. doi: 10.1126/scitranslmed.3009098
   Web of Science ®Google Scholar
• Halilbasic E, Steinacher D, Trauner M. Nor-Ursodeoxycholic Acid as a novel therapeutic approach for cholestatic and metabolic liver diseases. Dig Dis. 2017;35(3):288–292. doi: 10.1159/000454904
   PubMed Web of Science ®Google Scholar
• Kuipers F, Bloks VW, Groen AK. Beyond intestinal soap - Bile acids in metabolic control. Nat Rev Endocrinol. 2014;10(8):488–98.
   PubMed Web of Science ®Google Scholar
• Ghallab A, González D, Strängberg E, et al. Inhibition of the Renal Apical Sodium Dependent Bile Acid Transporter Prevents Cholemic Nephropathy in Mice with Obstructive Cholestasis. J Hepatol. 2023;
   PubMed Web of Science ®Google Scholar
• Almes M, Jobert A, Lapalus M, et al. Glycerol phenylbutyrate therapy in progressive familial intrahepatic cholestasis type 2. J Pediatr Gastroenterol Nutr. 2020;70(6):E139. doi: 10.1097/MPG.0000000000002713
   PubMed Web of Science ®Google Scholar
• Hinderer C, Katz N, Buza EL, et al. Severe toxicity in nonhuman primates and piglets following high-dose intravenous administration of an Adeno-Associated Virus Vector Expressing Human SMN. Hum Gene Ther. 2018;29(3):285–298. doi: 10.1089/hum.2018.015
   PubMed Web of Science ®Google Scholar
• Aronson SJ, Bakker RS, Shi X, et al. Liver-directed gene therapy results in long-term correction of progressive familial intrahepatic cholestasis type 3 in mice. J Hepatol. 2019;71(1):153–162. doi: 10.1016/j.jhep.2019.03.021
   PubMed Web of Science ®Google Scholar
• De Vree JML, Ottenhoff R, Bosma PJ, et al.. Correction of liver disease by hepatocyte transplantation in a mouse model of progressive familial intrahepatic cholestasis. Gastroenterology. 2000;119(6):1720–1730. doi: 10.1053/gast.2000.20222
   PubMed Web of Science ®Google Scholar
• Daya S, Berns KI. Gene therapy using adeno-associated virus vectors. Clin Microbiol Rev. 2008;21(4):583–593. doi: 10.1128/CMR.00008-08
   PubMed Web of Science ®Google Scholar
• Cunningham SC, Spinoulas A, Carpenter KH, et al. AAV2/8-mediated correction of OTC deficiency is robust in adult but not neonatal Spfash mice. Mol Ther. 2009;17(8):1340–1346. doi: 10.1038/mt.2009.88
   PubMed Web of Science ®Google Scholar
• Johns Hopkins University. Online Mendelian Inheritance in Man PFIC [Internet]. 2023. Available from: https://www.omim.org/search?index=entry&start=1&limit=10&sort=score+desc%2C+prefix_sort+desc&search=pfic
   Google Scholar
• Gudbjartsson DF, Helgason H, Gudjonsson SA, et al. Large-scale whole-genome sequencing of the Icelandic population. Nat Genet. 2015;47(5):435–444. doi: 10.1038/ng.3247
   PubMed Web of Science ®Google Scholar
• Tougeron D, Fotsing G, Barbu V, et al. ABCB4/MDR3 gene mutations and cholangiocarcinomas. J Hepatol. 2012;57(2):467–468. doi: 10.1016/j.jhep.2012.01.025
   PubMed Web of Science ®Google Scholar
• Jacquemin E, DeVree JML, Cresteil D, et al. The wide spectrum of multidrug resistance 3 deficiency: From neonatal cholestasis to cirrhosis of adulthood. Gastroenterology. 2001;120(6):1448–58.
   PubMed Web of Science ®Google Scholar
• Kamarajah S, Patten D, Wadkin J, et al. Reduced expression of TJP-2 is associated with chronic liver disease and hepatic malignancy. Gut. 2016;65(1):A159.
   Google Scholar
• Sambrotta M, Thompson RJ. Mutations in TJP2, encoding zona occludens 2, and liver disease. Tissue Barriers. 2015;3(3):1–5. doi: 10.1080/21688370.2015.1026537
   Google Scholar
• Amirneni S, Haep N, Gad MA, et al. Molecular overview of progressive familial intrahepatic cholestasis. World J Gastroenterol. 2020;26(47):7470–7484. doi: 10.3748/wjg.v26.i47.7470
   PubMed Web of Science ®Google Scholar
• Gissen P, Arias IM. Structural and functional hepatocyte polarity and liver disease. J Hepatol. 2015;63(4):1023–1037. doi: 10.1016/j.jhep.2015.06.015
   PubMed Web of Science ®Google Scholar
• Gonzales E, Taylor SA, Davit-Spraul A, et al. MYO5B mutations cause cholestasis with normal serum gamma-glutamyl transferase activity in children without microvillous inclusion disease. Hepatology. 2017;65(1):164–173. doi: 10.1002/hep.28779
   PubMed Web of Science ®Google Scholar
• Bull LN, Ellmers R, Foskett P, et al. Cholestasis Due to USP53 deficiency. J Pediatr Gastroenterol Nutr. 2021;72(5):667–673. doi: 10.1097/MPG.0000000000002926
   PubMed Web of Science ®Google Scholar
• Samanta A, Parveen N, Sen Sarma M, et al. Cholestatic liver disease due to novel USP53 mutations: a case series of three Indian children. J Clin Exp Hepatol. 2024;14(2):101290. doi: 10.1016/j.jceh.2023.10.001
   PubMed Web of Science ®Google Scholar
• Nakagawa T, Tanaka Y, Matsuoka E, et al. Identification and classification of 16 new kinesin superfamily (KIF) proteins in mouse genome. Proc Natl Acad Sci U S A. 1997;94(18):9654–9659. doi: 10.1073/pnas.94.18.9654
   PubMed Web of Science ®Google Scholar
• Stalke A, Sgodda M, Cantz T, et al. KIF12 Variants and Disturbed Hepatocyte Polarity in Children with a Phenotypic Spectrum of Cholestatic Liver Disease. J Pediatr. 2022;240:284–91.
   PubMed Web of Science ®Google Scholar
• Luan W, Hao CZ, Li JQ, et al. Biallelic loss-of-function ZFYVE19 mutations are associated with congenital hepatic fibrosis, sclerosing cholangiopathy and high-GGT cholestasis. J Med Genet. 2021;58(8):514–525. doi: 10.1136/jmedgenet-2019-106706
   PubMed Web of Science ®Google Scholar
• Mandato C, Siano MA, Nazzaro L, et al. A ZFYVE19 gene mutation associated with neonatal cholestasis and cilia dysfunction: case report with a novel pathogenic variant. Orphanet J Rare Dis. 2021;16(1):1–9. doi: 10.1186/s13023-021-01775-8
   PubMed Web of Science ®Google Scholar
• Wu SH, Chang MH, Chen YH, et al. The ESCRT-III molecules regulate the apical targeting of bile salt export pump. J Biomed Sci. 2021;28(1):1–18. doi: 10.1186/s12929-020-00706-2
   PubMed Web of Science ®Google Scholar
• Satomura Y, Bessho K, Nawa N, et al. Novel gene mutations in three Japanese patients with ARC syndrome associated mild phenotypes: a case series. J Med Case Rep. 2022;16(1):1–6. doi: 10.1186/s13256-022-03279-w
   PubMedGoogle Scholar
• Fu K li, Chen P, Zhou Y ying, et al. Hepatic Vps33b deficiency aggravates cholic acid-induced cholestatic liver injury in male mice. Acta Pharmacol Sin. 2022;43(4):933–40.
   PubMed Web of Science ®Google Scholar